早期妊娠丢失后游离胎儿DNA检测时间窗及影响因素
该前瞻性队列研究纳入1463名早期妊娠丢失女性,分析游离胎儿DNA(cffDNA)在组织排出后的下降规律。结果显示cffDNA逐渐下降,组织排出后3天内仍可检测到,但30%样本无结论;β-hCG水平较高与检测结论性相关(OR 1.30)。
要点
- 妊娠丢失后cffDNA逐渐下降,组织排出后3天内仍可检测到。
- 组织排出12小时后胎儿分数显著下降,无结论率增加。
- 较高β-hCG水平与cffDNA检测结论性正相关。
核心结论
- 妊娠丢失后cffDNA逐渐下降,组织排出后3天内仍可检测到,且与β-hCG下降相关。
研究设计与样本
- 前瞻性队列研究,纳入哥本哈根妊娠丢失(COPL)队列中1463名早期妊娠丢失女性, enrolled between 12 November 2020 and 19 December 2022。
- 参与者分为标准组(组织排出前采样)、延迟采样组(组织排出后最多24小时内采样)和重复采样组(药物和手术治疗后多个时间点采样)。
主要发现
- 组织排出后cffDNA和β-hCG水平随时间一致下降,无结论率相应增加。
- 胎儿分数在组织仍位于宫内时最高,组织排出后超过12小时显著下降(中位数4.7% <6小时 vs 2.8% >12小时)。
- 无结论率在组织仍原位时为9.1%,在组织排出后12-24小时组增至27.1%。
- 较高β-hCG水平与cffDNA检测结论性几率增加相关(OR 1.30, 95% CI: 1.20-1.43, P < 0.001)。
- β-hCG解释了胎儿分数测量变异的20%。
关键数值与推荐
- 组织排出后3天时30%样本无结论。
- 胎儿分数中位数:组织排出后<6小时为4.7%,>12小时为2.8%。
- 无结论率:组织原位时9.1%,组织排出后12-24小时为27.1%。
- β-hCG与结论性检测的OR为1.30(95% CI: 1.20-1.43, P < 0.001)。
临床怎么用
- cffDNA检测可在妊娠丢失后3天内进行,但需注意无结论率随时间的增加。
- β-hCG水平可帮助优化测序决策,较高水平时检测结论性更高。
- 对于时间敏感生殖决策或复发性妊娠丢失的夫妇,cffDNA检测提供关键遗传信息。
局限性
- 重复采样组样本量小,可能限制研究结果的普遍性。
- 依赖SeqFF方法引入变异性,可能表现不一致。
- 虽调整了BMI、孕周、妊娠丢失类型和采样时间等关键混杂因素,但不能排除残余混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: How fast does cell-free fetal DNA (cffDNA) decline after early pregnancy loss and which factors affect the decline? SUMMARY ANSWER: After pregnancy loss cffDNA declines gradually with detectable levels persisting up to 3 days post-tissue passage correlating with β-hCG decline. WHAT IS KNOWN ALREADY: Postpartum clearance of cffDNA occurs within hours, but little is known about its decline following early pregnancy loss. Initial results from the Copenhagen Pregnancy Loss (COPL) study showed slower clearance in relation to pregnancy loss with detectable levels found up to 24 h after tissue passage. STUDY DESIGN, SIZE, DURATION: This prospective cohort study included 1463 women from the COPL cohort, enrolled between 12 November 2020 and 19 December 2022. Participants were divided into three groups based on sampling time: the standard group (samples collected before tissue passage), the delayed sample group (samples collected after tissue passage at maximum 24 h), and the repeated sample group (samples collected at multiple time points after medical and surgical treatment). PARTICIPANTS/MATERIALS, SETTING, METHODS: Eligible women were 18 years old with a confirmed intrauterine pregnancy loss before 22 gestational weeks. Exclusion criteria included ectopic, molar, or unknown-location pregnancies and inability to consent. For the repeated sample group, additional exclusions were vaginal bleeding at diagnosis, anembryonic pregnancies, and opting for expectant management. Blood samples were analyzed for β-hCG and cffDNA, with fetal fraction measured using the sequencing-based fetal fraction (SeqFF) method. In the repeated sampling group, analyses were performed on Days 2 and 3 for surgically treated and Days 7 and 14 for medically treated. MAIN RESULTS AND THE ROLE OF CHANCE: After pregnancy tissue passage, both cffDNA and β-hCG levels declined consistently over time with a corresponding increase in no-call rates. The decline in SeqFF following pregnancy loss occurred more gradually than the immediate clearance previously reported after delivery, remaining measurable for up to 3 days after pregnancy loss, though 30% of samples became inconclusive at this timepoint. The fetal fraction of cffDNA was highest when tissue remained in utero and declined significantly beyond 12-h post-passage (median 4.7% <6 h vs 2.8% >12 h). The no call rate was 9.1% when the tissue was still in situ but increased to 27.1% in the 12- to 24-h post-passage group. Higher β-hCG levels correlated with increased odds of a conclusive cffDNA test (OR 1.30, 95% CI: 1.20-1.43, P < 0.001). β-hCG is accounting for 20% of the variability in fetal fraction measurements. Variability in the decline of cffDNA between groups reflects the differences in the timing of sampling and treatment approaches. LIMITATIONS, REASONS FOR CAUTION: The small size of the repeated sample group may limit the generalizability of the findings. Reliance on the SeqFF method introduces variability, as it may not perform consistently. Adjustment for key confounders including BMI, gestational age, type of pregnancy loss, and timing of sampling was performed, but residual confounding cannot be ruled out. WIDER IMPLICATIONS OF THE FINDINGS: As a non-invasive method, cffDNA testing offers critical genetic insights for couples facing time-sensitive reproductive decisions or those with recurrent pregnancy loss. The correlation between β-hCG and fetal fraction suggests β-hCG screening could optimize sequencing decisions. These findings support refining cffDNA diagnostics to enhance pregnancy loss evaluation and reproductive care. STUDY FUNDING/COMPETING INTEREST(S): The study was funded by the Ole Kirks Foundation, the BioInnovation Institute Foundation (BII21SG1020554, NNF20SA0066125, and NNF15OC0016662), the Novo Nordisk Foundation (NNF22OC0077221 and NNF23OC0087269), and the A.P. Møller Foundation. The authors have declared their COI. TRIAL REGISTRATION NUMBER: N/A.
引用
- El Sammaa-Aru YI, Hartwig TS, Bro-Jørgensen MH, et al. How big is the time window for cell-free fetal DNA testing after pregnancy loss and which factors are associated with a successful result? Hum Reprod. 2026. PMID: 41875045. doi:10.1093/humrep/deag034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。